Lymphangiogenesis new mechanisms.

VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest (2004) 5.59

Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest (2005) 3.77

Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. Am J Pathol (2007) 2.27

Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res (2010) 1.33

The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. Lymphat Res Biol (2010) 1.27

Novel expression and characterization of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1) by conjunctival cells. Invest Ophthalmol Vis Sci (2005) 1.22

Differential distribution of blood and lymphatic vessels in the murine cornea. Invest Ophthalmol Vis Sci (2009) 1.17

Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3 signaling. Am J Pathol (2005) 1.09

Experimental models to study lymphatic and blood vascular metastasis. J Surg Oncol (2011) 1.07

Regulation of blood vessel versus lymphatic vessel growth in the cornea. Invest Ophthalmol Vis Sci (2008) 1.05

Potential therapeutic strategies for lymphatic metastasis. Microvasc Res (2007) 0.92

The extra domain A of fibronectin increases VEGF-C expression in colorectal carcinoma involving the PI3K/AKT signaling pathway. PLoS One (2012) 0.89

Clinicopathological correlation analysis of (lymph) angiogenesis and corneal graft rejection. Mol Vis (2011) 0.86

The Role of PPARs in the Endothelium: Implications for Cancer Therapy. PPAR Res (2008) 0.81

New advances in targeted gastric cancer treatment. World J Gastroenterol (2016) 0.81

Model of Vascular Desmoplastic Multispecies Tumor Growth. J Theor Biol (2017) 0.75

Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 6.58

A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst (2006) 4.44

Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature (2009) 3.93

Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst (2002) 3.77

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res (2007) 3.53

Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood (2007) 3.38

Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle (2006) 3.10

Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A (2003) 3.10

Platelets actively sequester angiogenesis regulators. Blood (2008) 2.47

PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest (2002) 2.31

A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol (2005) 2.14

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol (2002) 2.10

Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature (2008) 2.09

Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A (2006) 2.09

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res (2009) 2.04

Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest (2004) 2.03

Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A (2004) 1.98

Endostatin's antiangiogenic signaling network. Mol Cell (2004) 1.95

Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol (2008) 1.93

Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res (2009) 1.90

Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A (2006) 1.89

Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr (2009) 1.89

Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A (2007) 1.85

Stem cell therapies benefit Alport syndrome. J Am Soc Nephrol (2009) 1.83

Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood (2010) 1.81

PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A (2008) 1.80

Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest (2011) 1.74

Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics (2005) 1.72

Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med (2004) 1.70

Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics (2006) 1.60

Blue rubber bleb nevus syndrome: surgical eradication of gastrointestinal bleeding. Ann Surg (2005) 1.59

Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood (2009) 1.57

Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat (2010) 1.57

Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro. Blood (2006) 1.53

Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther (2008) 1.47

Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability. FASEB J (2008) 1.46

Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med (2006) 1.42

Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res (2004) 1.42

The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study. J Pediatr Surg (2005) 1.39

Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis (2008) 1.38

Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell (2005) 1.37

Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev (2010) 1.36

Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg (2003) 1.34

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol (2007) 1.34

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res (2005) 1.33

Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res (2005) 1.33

Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res (2005) 1.33

Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci U S A (2005) 1.28

PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther (2005) 1.28

Platelet-associated PF-4 as a biomarker of early tumor growth. Blood (2007) 1.26

PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS One (2007) 1.24

Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res (2006) 1.23

Radiation abscopal antitumor effect is mediated through p53. Cancer Res (2003) 1.22

Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J (2006) 1.21

An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat Biotechnol (2008) 1.19

Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res (2004) 1.19

Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol (2008) 1.18

ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res (2005) 1.16

Tumor-vascular interactions and tumor dormancy. APMIS (2008) 1.16

Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol (2003) 1.16

2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol (2008) 1.14

Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci U S A (2012) 1.12

VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis (2012) 1.12

Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics (2002) 1.12

Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res (2007) 1.11

A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res (2005) 1.10

Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril (2005) 1.08

Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia (2003) 1.08

Epoxyeicosanoids promote organ and tissue regeneration. Proc Natl Acad Sci U S A (2013) 1.08

Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res (2003) 1.06

Freeze-dried platelet-rich plasma shows beneficial healing properties in chronic wounds. Wound Repair Regen (2006) 1.05

Adipose tissue growth and regression are regulated by angiopoietin-1. Biochem Biophys Res Commun (2003) 1.05

Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice. Surgery (2002) 1.04

A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am J Pathol (2006) 1.03

A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell (2003) 1.03

Dendritic cells support angiogenesis and promote lesion growth in a murine model of endometriosis. FASEB J (2007) 1.02

Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol (2010) 1.02

Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertil Steril (2006) 1.01

Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest (2004) 1.00

Consensus micro RNAs governing the switch of dormant tumors to the fast-growing angiogenic phenotype. PLoS One (2012) 0.99

Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J (2002) 0.96

Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. Clin Cancer Res (2008) 0.95

Dendritic cells augment choroidal neovascularization. Invest Ophthalmol Vis Sci (2008) 0.94

Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs (2003) 0.94

Angiogenesis inhibitors and hypoxia. Nat Med (2003) 0.94

Genes tell lymphatics to sprout or not. Nat Immunol (2004) 0.93

The route of lipid administration affects parenteral nutrition-induced hepatic steatosis in a mouse model. J Pediatr Surg (2005) 0.93

CDK2 translational down-regulation during endothelial senescence. Exp Cell Res (2005) 0.93

Endothelial progenitor cells contribute to accelerated liver regeneration. J Pediatr Surg (2007) 0.93

Circulating endothelial progenitor cells are up-regulated in a mouse model of endometriosis. Am J Pathol (2011) 0.93

Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib. Ann Surg (2005) 0.92

Binding inhibition of angiogenic factors by heparan sulfate proteoglycans in aqueous humor: potential mechanism for maintenance of an avascular environment. FASEB J (2003) 0.92

Tensile forces stimulate vascular remodeling and epidermal cell proliferation in living skin. Ann Surg (2007) 0.92

Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol (2005) 0.91

Maintenance of G1 checkpoint controls in telomerase-immortalized endothelial cells. Cell Cycle (2004) 0.89